缺氧诱导基因结构域家族构件1A在结直肠癌中的表达及其临床意义

Expression and clinical significance of hypoxia inducible domain family member 1A in colorectal cancer

目的观察结直肠癌患者中缺氧诱导基因结构域家族构件1A(HIGD1A)的表达及对于肿瘤预后的影响。方法免疫组织化学分析江南大学附属医院2008年1月至2011年12月行结直肠癌根治术的157例患者中HIGD1A的表达,收集年龄、性别、肿瘤浸润深度、肿瘤部位(结肠或直肠)、淋巴结转移、神经侵犯、脉管内癌栓、TNM分期等临床病理参数,随访总生存期(overall survival,OS),组间比较采用。结果HIGD1A在结直肠癌中低表达组为93例(59.2%),高表达组为64例(40.8%)。HIGD1A高表达组在Ⅰ~Ⅱ期的表达率为50.6%,明显高于在Ⅲ~Ⅳ期中的表达率(49.4%,χ2=6.115,P<0.05)。在不同TNM分期的患者中的表达差异有统计学意义(P<0.05),与年龄、性别、肿瘤浸润深度、肿瘤部位(结肠或直肠)、淋巴结转移、神经侵犯、脉管内癌栓等临床病理参数无明显相关(P>0.05)。HIGD1A低表达组的OS为(73.6±3.5)个月;HIGD1A高表达组的OS为(89.5±3.0)个月,明显高于HIGD1A低表达组(χ2=11.183,P<0.05)。多因素风险比例模型显示,HIGD1A[风险比(HR)=0.315,95%可信区间(CI)=0.135~0.738,P<0.05]可作为评估预后的独立危险因素。结论HIGD1A的表达有助于评判结直肠癌的预后。

Objective To observe the expression of hypoxia inducible domain family member 1A(HIGD1A)and its effect on tumor prognosis in patients with colorectal cancer.Methods The expression of HIGD1A in 157 patients with colorectal cancer was analyzed by immunohistochemistry,the clinicopathological parameters were collected,and the overall survival(OS)was followed up.SPSS software was used for statistical analysis.Results A total of 93 cases(59.2%)were in the low expression group and 64 cases(40.8%)in the high expression group of colorectal cancer.There were significant differences in the expression of HIGD1A in patients with different TNM stages(P<0.05).There was no significant difference in clinicopathological parameters such as ages,gender,invasion depth,tumor loctions,lymphatic metastasis,never invasion,intravascular tumor thrombus(P>0.05).The OS of the low expression group of HIGD1A was(73.6±3.5)months.The OS of the high expression group of HIGD1A was(89.5±3.0)months,which was significantly longer than that of the low expression group of HIGD1A.The multi-factor risk ratio model showed that HIGD1A[hazard ratio(HR)=0.315,95%confidence interval(CI)=0.135-0.738,P<0.05]could be used as an independent risk factor to evaluate the prognosis.Conclusion The expression of HIGD1A helps evaluating the prognosis of colorectal cancer.